Cantor Fitzgerald analyst Alethia Young says Stemline Therapeutics' long-term trajectory remains intact after the company announced a Q4 sales miss for Elzonris. The analyst thinks the miss is likely due to the orphan nature of blastic plasmacytoid dendritic cell neoplasm. Management has noted the lumpiness of sales when guiding expectations previously, Young tells investors in a research note. With the stock down more than 20% post market, the analyst thinks investors are concerned about the sales trajectory. She expects quarter-to-quarter fluctuation for sales this year but maintains her view that Elzonris has both near- and long-term growth potential.